Craniopharyngioma With Tumoral Hemorrhage

Clinical data of 185 consecutive patients receiving resective operation with a pathological diagnosis of craniopharyngioma in our hospital between January 2013 and February 2021 were collected. Among these patients, 18 of them were recognized as craniopharyngioma with tumoral hemorrhage during the operation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Craniopharyngioma Apoplexy Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Nervous System Diseases Neuroectodermal Tumors Stroke Vascular Diseases

Sex eligibility

All sexes

Study type

Observational

About this study

For each case, age, gender, smoking status, alcohol intake, past history, symptoms, blood pressure, blood cell count, blood biochemical tests, coagulation tests, hormone tests, radiological results, surgical treatment and the outcome at discharge were collected. The first test result after admission and before the operation was taken for the items of blood tests with multiple times in the analysis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

receive resective operation with a pathological diagnosis of craniopharyngioma in our hospital
enter our hospital between January 2013 and February 2021

Exclusion criteria

have a non-craniopharyngioma or unverified pathological diagnosis at discharge
have received surgical or radiological treatment on the sellar region
receive treatment of coagulation modulation, immunosuppressive agents or chemotherapeutic drugs
combine with other clinical emergencies including acute myocardial infarction, cerebral stroke, trauma and sepsis at admission
have been diagnosed with other tumors, hematological diseases, autoimmune diseases, liver failure or renal failure

Treatment and study plan

intratumoral hemorrhage

Other

Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.

Primary outcomes

craniopharyngioma with tumoral hemorrhage

Time frame: during the operation

Current study is a case-control study whose primary outcome is tumoral hemorrhage observed during the operation, which devided the craniopharyngioma patients into hemorrhage group and non-hemorrhage group.

Sponsors and collaborators

Lead sponsor

Tongji Hospital

Other

Registry information

Official study title

Clinical Features and Risk Factors of Craniopharyngioma With Tumoral Hemorrhage

Important dates

Study start: 2013
Primary completion: 2021
Study completion: 2021
First posted: Jun 24, 2021
Registry last updated: Jun 24, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed